Alliance urges Congress to up FDA budget by 20%

Share this article:
The FDA Alliance, an industry-supported group formed to increase public funding of the FDA, says Congress should raise President Bush’s FY 2008 budget request for the agency by 20% to an appropriation of $2 billion.

This amount, the Alliance says, would restore the agency to the operational capabilities it had in FY 2003 and enable it carry out the public health and safety program initiatives funded by Congress since then.

The budget request being considered on Capitol Hill seeks $1.64 billion for the FDA, not counting $450 million in user fees paid by industry. The FDA Alliance’s $2 billion recommendation is in addition to user fees.

According to Alliance documents, much of the historic underfunding of the FDA can be attributed to the failure to fund the personnel costs required to fulfill the agency’s sweeping mission, which consume 83% of its total budget.

“Currently, Congress appropriates just $4.94 per American per year (excluding user fees) to the FDA,” the documents say. “At $2 billion in appropriated funds (budget authority) for FY08, this would still represent only $6.67 per American being spent on helping FDA to keep pace with its vital missions and services.”

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in News

Email Newsletters

More in News

New lipid agents are high on potency, low on doc awareness

New lipid agents are high on potency, low ...

The new PCSK9 class of cholesterol-lowering antibodies continues to look promising, but many doctors—particularly PCPs—have never even heard of the experimental drugs.

Novartis may have game-changing drug

Novartis may have game-changing drug

Key opinion leaders indicate they are ready to embrace Novartis's experimental heart failure medication LCZ696. Such a move could upend heart failure treatment protocols.

Five things for pharma marketers to know: Tuesday, September 2

Five things for pharma marketers to know: Tuesday, ...

Sanofi and Regeneron unveil Phase-III results of their PCSK9; Merck will present data on its anti-PD-1 at the end of this month; WSJ op/ed suggests US should lead fight against ...